Scholarlink

Background <p>Real-world data describing contemporary hyperbaric oxygen therapy (HBOT) practice in Italy are limited. This study aimed to describe current clinical indications and therapeutic modalities of HBOT at the national level.</p> Methods <p>We conducted a multicentre, prospective, observational national study, promoted by Italian Society of Anesthesia Analgesia, Resuscitation and Intensive Care (SIAARTI). We included consecutive patients who underwent HBOT in 10 study centres within a period of 12&#xa0;weeks, for any treatment indication. The primary outcome of the study was the proportion of treatments by clinical indication and urgency of treatment.</p> Results <p>Overall, 327 patients were included across 10 centres, of which 73.7% (<i>n</i> = 241) received elective and 26.3% (<i>n</i> = 86) urgent treatments. The most frequent indication was sudden hearing loss (35.8%), followed by carbon monoxide poisoning (19.9%) and soft tissue infection (12.2%). Treatments were delivered at a median of 2.5 ATA, with two oxygen cycles for session and a median of 16 sessions for patients. No serious adverse events occurred.</p> Conclusions <p>In Italy, HBOT is applied in accordance with national and international guidelines. The most frequent indications to treatment were sudden hearing loss, carbon monoxide poisoning, and soft tissue infections. Treatments had similar characteristics across the centres, with heterogeneity mainly regarding the number of sessions per patient. </p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Indications, therapeutic modalities and clinical outcomes of hyperbaric oxygen therapy in Italy, the ITA-OTI Study: a multicentre prospective observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Mariachiara Ippolito,
  • Luca Martani,
  • Alberto Noto,
  • Laura Maniscalco,
  • Giulia Spurio,
  • Marina Nasello,
  • Salvatore Sardo,
  • Vincenzo Francesco Tripodi,
  • Savino Borraccino,
  • Luigi Giancarlo Vicari Sottosanti,
  • Carlotta Ferraro,
  • Luca Cantadori,
  • Andrea Neville Cracchiolo,
  • Luigi Targa,
  • Fiorenzo Fracasso,
  • Andrea Giovaniello,
  • Fiammetta Ronga,
  • Claudio Spena,
  • Elena Giovanna Bignami,
  • Domenica Matranga,
  • Antonino Giarratano,
  • Andrea Cortegiani,
  • Vincenzo Benenati,
  • Giulia Catalisano,
  • Emanuele Corallo,
  • Ilde Covino,
  • Sarah Di Miceli,
  • Fabio Favorito,
  • Andrea Galvani,
  • Carmelo Gigliuto,
  • Alessandro Marchignoli,
  • Anna Teresa Mazzeo,
  • Francesca Moretto,
  • Dario Nicosia,
  • Carolina Nuzzo,
  • David Pacchioli,
  • Daniela Maria Palma,
  • Barbara Pifferi,
  • Gabriele Presti,
  • Nadia Stagni,
  • Rosanna Vaschetto

摘要

Background

Real-world data describing contemporary hyperbaric oxygen therapy (HBOT) practice in Italy are limited. This study aimed to describe current clinical indications and therapeutic modalities of HBOT at the national level.

Methods

We conducted a multicentre, prospective, observational national study, promoted by Italian Society of Anesthesia Analgesia, Resuscitation and Intensive Care (SIAARTI). We included consecutive patients who underwent HBOT in 10 study centres within a period of 12 weeks, for any treatment indication. The primary outcome of the study was the proportion of treatments by clinical indication and urgency of treatment.

Results

Overall, 327 patients were included across 10 centres, of which 73.7% (n = 241) received elective and 26.3% (n = 86) urgent treatments. The most frequent indication was sudden hearing loss (35.8%), followed by carbon monoxide poisoning (19.9%) and soft tissue infection (12.2%). Treatments were delivered at a median of 2.5 ATA, with two oxygen cycles for session and a median of 16 sessions for patients. No serious adverse events occurred.

Conclusions

In Italy, HBOT is applied in accordance with national and international guidelines. The most frequent indications to treatment were sudden hearing loss, carbon monoxide poisoning, and soft tissue infections. Treatments had similar characteristics across the centres, with heterogeneity mainly regarding the number of sessions per patient.

Clinical trial number

Not applicable.